^
    9d
    Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • tiragolumab (RG6058)
    9d
    VELOCITY-Lung: Study of Novel Treatment Combinations in Patients With Lung Cancer (clinicaltrials.gov)
    P2, N=192, Active, not recruiting, Gilead Sciences | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • Trodelvy (sacituzumab govitecan-hziy) • domvanalimab (AB154) • etrumadenant (AB928)
    23d
    Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=126, Not yet recruiting, Sinocelltech Ltd.
    New P1/2 trial
    25d
    Fc-enhanced anti-TIGIT antibody 30,278-IgG1 RMD amplifies antitumor immunity through effector cell activation and synergizes with PD-1 blockade. (PubMed, Clin Immunol)
    This variant was compared to wild-type IgG1, an Fc-inert IgG4, and tiragolumab in in vitro assays (TIGIT binding/blockade, ADCC, ADCP, Treg depletion, immune cell activation in human PBMCs) and in an hTIGIT/hPD-1 knock-in mouse colon carcinoma model (CT26) combined with PD-1 blockade...Fc engineering of an anti-TIGIT antibody substantially improves immune effector engagement and anti-tumor efficacy. Augmenting FcγR interactions alongside checkpoint blockade can potentiate T cell responses and drive tumor regression, underscoring the translational potential of Fc-optimized checkpoint immunotherapies.
    Journal
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    tiragolumab (RG6058)
    29d
    CPG-02-101: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies (clinicaltrials.gov)
    P1, N=94, Completed, Compugen Ltd | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Apr 2026 | Trial primary completion date: Dec 2025 --> Apr 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • COM701 • COM902
    30d
    AdvanTIG-302: A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer (clinicaltrials.gov)
    P3, N=669, Terminated, BeiGene | Active, not recruiting --> Terminated; This decision was conducted by the sponsor based on lack of efficacy and not driven by safety concerns.
    Trial termination
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    1m
    GEMINI-PeriOp GC: A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=100, Recruiting, AstraZeneca
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 positive • HER-2 negative • CLDN18.2 positive • CLDN18.2 positive + HER-2 negative
    |
    docetaxel • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936)
    1m
    Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Washington University School of Medicine | Trial completion date: Jun 2030 --> Dec 2030 | Trial primary completion date: Apr 2026 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928)
    1m
    D6187C00001: A trial to learn how safe different combinations of anti-cancer drugs are and how well they work in adults with advanced or metastatic non-small cell lung cancer (NSCLC) (2025-524843-11-00)
    P1/2, N=20, Not yet recruiting, AstraZeneca AB
    New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK rearrangement
    |
    Cyramza (ramucirumab) • rilvegostomig (AZD2936)
    1m
    Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma (clinicaltrials.gov)
    P1/2, N=10, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    1m
    MEDOPP0653: A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF THE COMBINATION OF ZIMBERELIMAB, DOMVANALIMAB, AND SACITUZUMAB GOVITECAN AS FIRST-LINE THERAPY FOR PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCER (The ADJUNCT Study) (2025-521489-80-00)
    P1/2, N=25, Completed, Medica Scientia Innovation Research S.L. | Not yet recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Yutuo (zimberelimab) • Trodelvy (sacituzumab govitecan-hziy) • domvanalimab (AB154)
    1m
    ADJUNCT: Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC (clinicaltrials.gov)
    P2, N=0, Withdrawn, MedSIR | N=25 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Yutuo (zimberelimab) • Trodelvy (sacituzumab govitecan-hziy) • domvanalimab (AB154)